

Applicant : Vladimir BAKHUTASHVILI
U.S. Serial No.: 10/795,819
Filing Date : March 8, 2004
Page : 2

AMENDMENTS TO THE CLAIMS:

Please cancel claims 2, 3, 23, 24, 65, 67 and 85-98 without prejudice to the Applicant's rights to pursue the subject matters in a future application, and add the following new claims:

1-98. (Canceled)

99. (New) A composition comprising an effective amount of a mixture for modulating apoptosis, the mixture being prepared from amniotic tissue products according to a method comprising the steps of:

- (a) obtaining and preparing an amniotic membrane from amniotic tissue products;
- (b) priming the amniotic cells in the amniotic membrane;
- (c) contacting an amount of a virus with the amniotic cells to form a suspension;
- (d) separating the amniotic membrane from the suspension; and
- (e) purifying the suspension to obtain the composition.

100. (New) The composition of claim 99, wherein the amniotic membrane is obtained from healthy mothers after normal delivery of a healthy infant.

101. (New) The composition of claim 99, wherein step (a) further comprises removing the placenta and blood clots from the amniotic membrane, and cutting the amniotic membrane into appropriate sizes.

Applicant : Vladimir BAKHUTASHVILI
U.S. Serial No.: 10/795,819
Filing Date : March 8, 2004
Page : 3

102. (New) The composition of claim 101, wherein step (a) further comprises incubating amniotic membrane for 30 minutes at 37°C.

103. (New) The composition of claim 99, comprising a bioactive fraction characterized by the peaks shown in figure 2 or 3, wherein the bioactive is prepared according to a method comprising the steps of: purifying the composition to obtain a low molecular weight fraction, wherein the low molecular weight fraction is <10 Kda; and performing gel permeation chromatography and solid phase extraction on the low molecular weight fraction to obtain the bioactive fraction.

104. (New) The composition of claim 99, wherein the priming step (b) is performed for 2-3 hours at 37.5°C.

105. (New) The composition of claim 99, wherein the virus is Newcastle disease virus or a virus that does not reproduce in human cell cultures.

106. (New) The composition of claim 99, wherein the virus is type species "H" of Newcastle disease virus.

107. (New) The composition of claim 99, wherein step (c) is performed for 1-2 hours at 37.5°C.

108. (New) The composition of claim 107, wherein step (c) further comprises separating the non-absorbed virus.

109. (New) The composition of claim 108, wherein step (c) further comprises cultivating the amniotic membrane for 16-18 hours at 37.5°C.

Applicant : Vladimir BAKHUTASHVILI
U.S. Serial No.: 10/795,819
Filing Date : March 8, 2004
Page : 4

110. (New) The composition of claim 109, wherein step (c) further comprises adding an appropriate amount of an acid to inactivate the virus.

111. (New) The composition of claim 110, wherein step (c) further comprises screening the suspension for viruses of hepatitis B and C, and HIV.

112. (New) The composition of claim 111, wherein step (c) further comprises autoclaving the suspension.

113. (New) The composition of claim 112, wherein the suspension is autoclaved for 30 minutes at 120°C.

114. (New) The composition of claim 99, further comprising lyophilizing the composition.

115. (New) A composition an effective amount of a mixture for modulating apoptosis, the mixture being prepared from amniotic tissue products according to a method, comprising the steps of:

(a) obtaining a placenta from a subject after normal birth of an infant;

(b) separating amniotic membrane from the placenta;

(c) washing blood clot from the amniotic membrane;

(d) cutting the amniotic membrane into appropriate sizes;

(e) priming the amniotic cells in the amniotic membrane;

(c) contacting an amount of a virus with the amniotic cells to form a suspension;

Applicant : Vladimir BAKHUTASHVILI
U.S. Serial No.: 10/795,819
Filing Date : March 8, 2004
Page : 5

- (d) separating the amniotic membrane from the suspension; and
- (e) purifying the suspension to obtain the composition.

116. (New) The composition of claim 115, further comprising lyophilizing the composition.

117. (New) A composition comprising a mixture for modulating apoptosis prepared, the mixture being prepared from amniotic tissue products according to a method, comprising the steps of:

- (a) obtaining a placenta from a subject after normal birth of an infant;
- (b) separating amniotic membrane from the placenta;
- (c) washing blood clot from the amniotic membrane;
- (d) cutting the amniotic membrane into appropriate sizes;
- (e) preparing a suspension of amniotic membrane;
- (f) boiling the suspension to obtain a boiled suspension;
- (g) incubating the boiled suspension; and
- (h) purifying the boiled suspension to obtain the composition.

118. (New) The composition of claim 117, further comprising lyophilizing the composition.